The QJM has recently published reviews of novel therapies in chronic airways disease.1 There is a potentially novel role for glucagon-like peptide 1 (GLP-1) agonists in obesity-related, metabolic asthma, though clinical trial data are lacking.2 On the basis of work with other inflammatory states, we hypothesised that clinically-indicated use of GLP-1 agonists for glycaemic control in type 2 diabetes mellitus (T2DM) would be safe in those with concomitant asthma, potentially leading to improved asthma control and fewer asthma exacerbations.3 In a pilot observational cohort study, we prospectively identified nine patients with pulmonologist-diagnosed asthma (never-smokers) and concomitant T2DM who were about to be initiated on clinically-indicated liraglutide for T2DM in the course of routine clinical care, and assessed them for asthma-related indices at baseline and 52 weeks after initiating liraglutide. All received routine asthma care. Baseline characteristics of the study cohort are as shown (Table 1)...